MedDataX Logo

REBECCA Real-world Early BrEast CanCer mAnagement

NCT ID: NCT06856343

Last Updated: 2026-01-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

126 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-12-30

Study Completion Date

2028-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a French observational, national, multicenter prospective cohort study of patients with HER2-negative eBC treated with olaparib at their physician's discretion.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Observational Study of Avastin (Bevacizumab) in Patients With HER2-metastatic or Locally Advanced Breast Cancer

NCT01461044

Breast Cancer
COMPLETED

Safety, Effectiveness and Quality of Life of Trastuzumab Deruxtecan in Patients with HER2+ Breast Cancer

NCT05149014

HER2-positive Breast Cancer
COMPLETED

Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France

NCT05697146

Breast Cancer
ACTIVE_NOT_RECRUITING

A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With Neratinib

NCT05599334

Breast Cancer Adjuvant Therapy HER2-positive Breast Cancer
COMPLETED

Ibrance Real World Insights

NCT03159195

Malignant Neoplasm of Breast
COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose to this observational study is to evaluate the rate of completion of adjuvant Olaparib treatment for HER2-negative early breast cancer patients in France.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female aged ≥ 18 years
* Patient diagnosed with HER2-negative eBC
* Patient about to be initiated with adjuvant Olaparib at their physician's discretion
* Patient has been informed and does not object to participation in the study.

Exclusion Criteria

* Patient not consenting to participate.
* Patients included in the Early Access Program
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Agen, , France

Site Status NOT_YET_RECRUITING

Research Site

Argenteuil, , France

Site Status NOT_YET_RECRUITING

Research Site

Avignon, , France

Site Status NOT_YET_RECRUITING

Research Site

Beauvais, , France

Site Status NOT_YET_RECRUITING

Research Site

Beuvry, , France

Site Status NOT_YET_RECRUITING

Research Site

Bezannes, , France

Site Status NOT_YET_RECRUITING

Research Site

Caen, , France

Site Status NOT_YET_RECRUITING

Research Site

Chambray-lès-Tours, , France

Site Status RECRUITING

Research Site

Champigny-sur-Marne, , France

Site Status NOT_YET_RECRUITING

Research Site

Clermont-Ferrand, , France

Site Status RECRUITING

Research Site

Compiègne, , France

Site Status NOT_YET_RECRUITING

Research Site

Creil, , France

Site Status NOT_YET_RECRUITING

Research Site

Dechy, , France

Site Status NOT_YET_RECRUITING

Research Site

FORT de France Cedex, , France

Site Status NOT_YET_RECRUITING

Research Site

Fréjus, , France

Site Status NOT_YET_RECRUITING

Research Site

Gleizé, , France

Site Status RECRUITING

Research Site

Grenoble, , France

Site Status NOT_YET_RECRUITING

Research Site

Le Blanc-Mesnil, , France

Site Status NOT_YET_RECRUITING

Research Site

Lille, , France

Site Status NOT_YET_RECRUITING

Research Site

Limoges, , France

Site Status NOT_YET_RECRUITING

Research Site

Lyon, , France

Site Status NOT_YET_RECRUITING

Research Site

Marseille, , France

Site Status NOT_YET_RECRUITING

Research Site

Metz-Tessy, , France

Site Status RECRUITING

Research Site

Montpellier, , France

Site Status NOT_YET_RECRUITING

Research Site

Montpellier, , France

Site Status RECRUITING

Research Site

Nancy, , France

Site Status RECRUITING

Research Site

Nice, , France

Site Status NOT_YET_RECRUITING

Research Site

Osny, , France

Site Status NOT_YET_RECRUITING

Research Site

Paris, , France

Site Status NOT_YET_RECRUITING

Research Site

Périgueux, , France

Site Status NOT_YET_RECRUITING

Research Site

Plérin, , France

Site Status NOT_YET_RECRUITING

Research Site

Poitiers, , France

Site Status NOT_YET_RECRUITING

Research Site

Rouen, , France

Site Status RECRUITING

Research Site

Saint-Brieuc, , France

Site Status NOT_YET_RECRUITING

Research Site

Saint-Doulchard, , France

Site Status NOT_YET_RECRUITING

Research Site

Saint-Etienne, , France

Site Status NOT_YET_RECRUITING

Research Site

Saint-Grégoire, , France

Site Status RECRUITING

Research Site

Saint-Martin-Boulogne, , France

Site Status NOT_YET_RECRUITING

Research Site

Saint-Pierre-des-Corps, , France

Site Status NOT_YET_RECRUITING

Research Site

Saint-Priest-en-Jarez, , France

Site Status NOT_YET_RECRUITING

Research Site

Salouël, , France

Site Status NOT_YET_RECRUITING

Research Site

Thonon-les-Bains, , France

Site Status NOT_YET_RECRUITING

Research Site

Valence, , France

Site Status NOT_YET_RECRUITING

Research Site

Valence, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

AstraZeneca Clinical Study Information Center

Role: CONTACT

[email protected]
1-877-240-9479

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

D0817R00068

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer.
NCT00717405 COMPLETED PHASE2
Retroprospective Real Life Observatory of Eribulin
NCT02393287 COMPLETED
Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors:
NCT07180693 RECRUITING
Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line
NCT03462251 COMPLETED PHASE3
A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer
NCT02149524 COMPLETED PHASE3
Real-world Evaluation of Patient Outcomes and Experiences With Ribociclib Early Adopters.
NCT07243002 RECRUITING
A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer
NCT06188559 ACTIVE_NOT_RECRUITING PHASE2
UFT/LV Maintenance Vs Observation in Metastatic Breast Cancer Responsive to Chemotherapy
NCT00189631 UNKNOWN PHASE3
Early On-treatment Transcriptional Profiling as Predictor of Response in Early-stage HER2-positive Breast Cancer
NCT05912062 UNKNOWN
Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer
NCT03078751 COMPLETED PHASE2
Lynparza Breast Cancer Clinical Experience Investigation
NCT03590938 COMPLETED
A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer
NCT02613208 COMPLETED
Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer
NCT02402712 COMPLETED PHASE3
BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer
NCT02123823 COMPLETED PHASE1
Evaluation of Degree of Conversion of HER2 Receptor Between Primary Breast Cancer and Metastasis
NCT01377363 COMPLETED
A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
NCT02675231 COMPLETED PHASE2
Breast Cancer With Over-expression of erbB2-BRAINSTORM
NCT01064349 COMPLETED
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
NCT00528567 COMPLETED PHASE3
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
NCT02057133 ACTIVE_NOT_RECRUITING PHASE1
Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy
NCT01652560 UNKNOWN
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
NCT05467891 RECRUITING PHASE2
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)
NCT01250379 COMPLETED PHASE3
An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory
NCT01240421 APPROVED_FOR_MARKETING
Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer
NCT03433313 COMPLETED PHASE3
A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world Database
NCT06962969 NOT_YET_RECRUITING